Cartesian Therapeutics Inc (RNAC) Stock Price, Quote & News

Company Profile

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile derma...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 348 8698

Website: www.cartesiantherapeutics.com

Address:

7495 New Horizon Way, Frederick, United States

doDD22 Mar. 19 at 1:12 PM

$RNAC Felt something fishy with that pump Still watching and waiting

0 · Reply

azv134 Mar. 19 at 12:31 PM

$RNAC buying back today. This is ridiculously cheap

0 · Reply

Meydamax315 Mar. 19 at 9:01 AM

$RNAC what a disaster. I lost so much money on this dog shit.

0 · Reply

StocktwitsEarnings Mar. 19 at 9:00 AM

$RNAC Q4 '25 Earnings Results & Recap Cartesian Therapeutics, Inc. expects its existing cash, cash equivalents, and restricted cash of $126.9M as of December 31, 2025, to fund operating expenses and capital expenditures for at least the next 12 months.

0 · Reply

kimgysen Mar. 18 at 7:00 PM

$RNAC When you think it can't get worse lol

0 · Reply

LoveRetailFroth Mar. 16 at 3:47 PM

$DTIL My Bio additions this yr $RCKT $RNAC $PALI $SMMT

0 · Reply

kimgysen Mar. 13 at 3:56 PM

$RNAC

0 · Reply

patience_needed Mar. 11 at 4:24 PM

$RNAC Hey all. So what’s the latest on CVRs? Should we expect a payout of any sorts around the end of the month?? TIA

1 · Reply

LoveRetailFroth Mar. 11 at 2:13 PM

$RXRX Good Morning ☕️ Long travel. How are you guys holding up? $IOVA $RCKT $RNAC

1 · Reply

StockScanners Mar. 10 at 4:04 AM

$RNAC keep watch if this holds above 8.80

1 · Reply

Cartesian Therapeutics Announces New Employment Inducement Grants

Jan 9, 2026, 8:04 AM EST - 2 months ago

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

Dec 18, 2025, 4:05 PM EST - 3 months ago

Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors

Nov 17, 2025, 12:17 PM EST - 4 months ago

Cartesian: Maintaining Buy Rating For Expansion Of Descartes-08 For Myositis

Oct 3, 2025, 7:05 AM EDT - 6 months ago

Cartesian Therapeutics Announces New Employment Inducement Grant

Sep 9, 2025, 7:09 PM EDT - 6 months ago

Cartesian Therapeutics, Inc. (RNAC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Aug 28, 2025, 7:00 AM EDT - 7 months ago

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

May 30, 2025, 7:00 AM EDT - 10 months ago

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

May 8, 2025, 7:00 AM EDT - 11 months ago

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 8, 2025, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Apr 1, 2025, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Jan 27, 2025, 7:00 AM EST - 1 year ago

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis

Dec 3, 2024, 6:00 AM EST - 1 year ago

Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

Nov 21, 2024, 7:00 AM EST - 1 year ago

Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

Nov 10, 2024, 12:26 PM EST - 1 year ago

Cartesian Therapeutics: Uncertainty Remains

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting

Sep 17, 2024, 9:45 AM EDT - 1 year ago

Cartesian Therapeutics Seems A 'Strong Buy' After Positive Phase 2 Results

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15

Jul 2, 2024, 4:05 PM EDT - 1 year ago

Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

Jul 2, 2024, 12:55 PM EDT - 1 year ago

Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data

Jul 2, 2024, 6:40 AM EDT - 1 year ago

Cartesian Therapeutics autoimmune disorder therapy meets main goal of mid-stage study

Jul 2, 2024, 6:31 AM EDT - 1 year ago

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

Jul 2, 2024, 6:31 AM EDT - 1 year ago

Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

Jul 2, 2024, 6:30 AM EDT - 1 year ago

Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

May 22, 2024, 7:00 AM EDT - 1 year ago

Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis

May 13, 2024, 4:30 PM EDT - 2 years ago

Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 8, 2024, 7:00 AM EDT - 2 years ago

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 22, 2024, 4:30 PM EDT - 2 years ago

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

Apr 4, 2024, 7:30 AM EDT - 2 years ago

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

Mar 7, 2024, 7:00 AM EST - 2 years ago

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Mar 5, 2024, 7:00 AM EST - 2 years ago

Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland

doDD22 Mar. 19 at 1:12 PM

$RNAC Felt something fishy with that pump Still watching and waiting

0 · Reply

azv134 Mar. 19 at 12:31 PM

$RNAC buying back today. This is ridiculously cheap

0 · Reply

Meydamax315 Mar. 19 at 9:01 AM

$RNAC what a disaster. I lost so much money on this dog shit.

0 · Reply

StocktwitsEarnings Mar. 19 at 9:00 AM

0 · Reply

kimgysen Mar. 18 at 7:00 PM

$RNAC When you think it can't get worse lol

0 · Reply

LoveRetailFroth Mar. 16 at 3:47 PM

$DTIL My Bio additions this yr $RCKT $RNAC $PALI $SMMT

0 · Reply

kimgysen Mar. 13 at 3:56 PM

$RNAC

0 · Reply

patience_needed Mar. 11 at 4:24 PM

$RNAC Hey all. So what’s the latest on CVRs? Should we expect a payout of any sorts around the end of the month?? TIA

1 · Reply

LoveRetailFroth Mar. 11 at 2:13 PM

$RXRX Good Morning ☕️ Long travel. How are you guys holding up? $IOVA $RCKT $RNAC

1 · Reply

StockScanners Mar. 10 at 4:04 AM

$RNAC keep watch if this holds above 8.80

1 · Reply

Arcides Mar. 10 at 1:32 AM

$RNAC this is already the highest weekly volume in its history..lets see if consolidates good, it has had many pops before that end up fading.

0 · Reply

BenGang Mar. 10 at 12:44 AM

$RNAC

0 · Reply

GSP Mar. 9 at 8:38 PM

$RNAC $DTCK $SLDB $ZVRA

0 · Reply

GSP Mar. 9 at 8:38 PM

$HIMS $RLMD $FJET $RNAC

0 · Reply

topstockalerts Mar. 9 at 4:06 PM

$RNAC Traders watching for updates after the last volatility cycle. Price stabilizing with tighter ranges forming. If it reclaims the breakdown area, sentiment could shift quickly.

0 · Reply

4976f2e Mar. 9 at 3:59 PM

$RNAC 2 million volume pre market. Huge buyer this morning. Looks like this will catch a nice ride up

0 · Reply

doDD22 Mar. 9 at 3:47 PM

$RNAC no real data for 2026 only enrollment data 2027? cash through mid-2027 cutting it close will wait

0 · Reply

theBigDollarski Mar. 9 at 3:43 PM

$RNAC wow....how many shorts are attached to this ticker??

0 · Reply

InjureReserve Mar. 9 at 3:20 PM

$RNAC https://ir.cartesiantherapeutics.com/news-releases/news-release-details/cartesian-therapeutics-reports-full-year-2025-financial-results

0 · Reply

Orlandotrader Mar. 9 at 2:32 PM

$RNAC Very Large Pre market volume!!! Possible Hedge Fund Addition????

0 · Reply

Quantumup Mar. 9 at 12:00 PM

Truist⬆️ $DNTH's PT to $110 from $63 and reiterated at a Buy. $SNY $ARGX NVS AZN $UCBJY $RNAC Truist said in its note—Dianthus announced an early "Go" decision for claseprubart in its CIDP program based on open-label Part A data that exceeded the ~50% response-rate threshold for advancement into the pivotal portion of the CAPTIVATE trial. The decision came earlier than expected after the company reached 20 confirmed INCAT responders before enrolling 40 patients in Part A. The original bar was a ~40-50% response rate (16-20 responders) among the first 40 patients. These results imply a response rate meaningfully above 50% and appear stronger than those reported by Sanofi's (SNY, NR) C1s inhibitor, riliprubart, in its open-label Phase 2 CIDP study (~50% response).

0 · Reply

ThomasTrainTrader Mar. 4 at 7:20 PM

$RNAC price action might seem random but it actually goes up on days where Carsten Brunn eats all of his supper including all the veggies, and it goes down when he doesn’t clean his plate

0 · Reply

Market Cap	172.57M
Revenue (ttm)	2.80M
Net Income (ttm)	-130.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,653.57%
Debt to Equity Ratio	0.00

Volume	106,500
Avg Vol	186,200
Day's Range	N/A - N/A
Shares Out	26.51M
Stochastic %K	5%
Beta	0.42
Analysts	Strong Sell
Price Target	$35.57